<DOC>
	<DOCNO>NCT01903018</DOCNO>
	<brief_summary>A Clinical Study Assess Radiation Induced Mucositis Subjects Locally Advanced Squamous Cell Carcinoma Head Neck</brief_summary>
	<brief_title>A Study Assess Radiation Induced Mucositis Patients Head Neck Cancer Administered Chemo-Radiation With Without P276-00</brief_title>
	<detailed_description>A Multicenter , Phase II/III Study Assess Radiation Induced Mucositis Subjects Locally Advanced Squamous Cell Carcinoma Head Neck Administered Cisplatin Radiation without P276-00 The Phase II component single arm , open label , multicenter study assess RIM subject locally advance SCCHN treat P276-00 combination radiation therapy cisplatin . ` The Phase III component randomize , assessor blind , multicenter , two-arm study compare time onset WHO Grade â‰¥ 3 RIM subject locally advance SCCHN ( OC , OP , HP , L ) receive definitive CRT treatment malignancy . Subjects receive definitive CRT receive weekly intravenous cisplatin administer radiation .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Able understand willing give inform consent study . 2 . Pathologically ( histologically cytologically ) confirm ( primary tumor and/or lymph node ) , nonmetastatic diagnosis squamous cell carcinoma oral cavity , oropharynx , hypopharynx , larynx eligible treatment concomitant chemoradiation firstline treatment ; subject history surgical management eligible 3 . Have plan receive continuous course radiation ( 3DRT IMRT ) single daily fraction 2.0 Gy , cumulative radiation dose 66 70 Gy . Planned radiation treatment field must include least 2 oral site ( maxillary mandibular labial mucosa , right leave buccal mucosa , right leave floor mouth , ventral tongue , right leave lateral tongue , soft palate ) , site receive equal 50 Gy 4 . Have plan receive standard cisplatin regimen administer weekly ( 30 40 mg/m2 ) 5 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status less equal 2 6 . Males female age 18 year old 7 . Pretreatment dental procedure must complete recovery prophylactic insertion gastric feed tube ( plan ) prior entry study 8 . Adequate bone marrow function measure within two week prior enrollment base upon CBC/differential , define follow : 1 . Absolute neutrophil count ( ANC ) equal 1,500 cells/mm3 2 . Platelets equal 100,000 cells/mm3 3 . Hemoglobin ( Hb ) equal 8.0 g/dl ( Note : The use transfusion intervention achieve Hb equal 8.0 g/dl prior start RT acceptable ) 9 . Adequate hepatic function measure within two week prior enrollment define follow 1 . Bilirubin le equal 1.5 mg/dl 2 . AST le equal 2 time ULN 3 . ALT le equal 2 time ULN 10 . Adequate renal function measure within two week prior enrollment define follow 1 . Serum creatinine less equal 1.5 mg/dl 2 . Creatinine clearance ( CC ) equal 60 ml/min determine 24hour urine collection estimate CockcroftGault formula : 11 . Have negative serum pregnancy test woman childbearing potential time screen negative urine pregnancy test within 72 hr prior first dose study drug 1 . Tumor lip , sinus , salivary gland , nasopharynx , unknown primary tumor 2 . Metastatic disease ( M1 ) Stage IVC per AJCC , 7th edition 3 . Prior radiation head neck 4 . Have undergone induction CT 5 . History malignant tumor HNC ( except nonmelanoma skin cancer ) unless disease free minimum 3 year 6 . Severe comorbidity , define : 1 . Symptomatic and/or uncontrolled cardiac disease , New York Heart Association Classification III IV 2 . Acute myocardial infarction within last 6 month 3 . Acute bacterial fungal infection require systemic antibiotic time enrollment 4 . Subjects know seropositive human immunodeficiency virus ( HIV ) subject Acquired Immune Deficiency Syndrome ( AIDS ) , know current acute chronic Hepatitis B , know Hepatitis C ( antigen positive ) , hepatic cirrhosis 5 . Subjects active tuberculosis 6 . Collagen vascular disease , scleroderma , think predispose subject increase risk radiationassociated toxicity 7 . Have use investigational drug therapy within 1 month prior Day 1 study drug administration nonrecovery ( Grade le equal 1 ) adverse effect investigational agent receive prior period 8 . Prior allergic reaction agent administered course treatment 9 . Have QTcF equal 450 msec screen 10 . Pregnant breastfeeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>